Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIRSWE)

• Drug Name: CYT-006-AngQb Drug Info
• Synonyms: AngQb; Immunodrug vaccines (hypertension), Cytos

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMIRSWE

Molecule-Related Drug Atlas

Drug(s) Targeting Angiotensin II receptor (AGTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DA-727	DM9KS1A	Hypertension	BA00-BA04	Phase 1	[3]
BIBR-363	DMGWFZJ	Hypertension	BA00-BA04	Discontinued in Phase 2	[4]
FK-739	DM7TLF6	Hypertension	BA00-BA04	Discontinued in Phase 2	[5]
ETRX-101	DMRB23N	Anemia	3A00-3A9Z	Discontinued in Phase 2	[6]
Elisartan potassium	DM0XF8J	Hypertension	BA00-BA04	Discontinued in Phase 2	[7]
ICI-D-8731	DM3R8TX	Hypertension	BA00-BA04	Discontinued in Phase 2	[8]
E-4177	DM2G7IP	Hypertension	BA00-BA04	Discontinued in Phase 2	[9]
CGP-48369	DMY8KO4	Hypertension	BA00-BA04	Discontinued in Phase 1	[10]
ICI-D-6888	DMZYA9E	Hypertension	BA00-BA04	Discontinued in Phase 1	[11]
DuP-532	DM59WQ7	Hypertension	BA00-BA04	Discontinued in Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor (AGTR)	TTGN1ZA	NOUNIPROTAC	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00710372) Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension. U.S. National Institutes of Health.
• [2] CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75.
• [3] WO patent application no. 2009,0880,06, Combined pharmaceutical agent.
• [4] Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system. Br J Clin Pharmacol. 1999 October; 48(4): 594-604.
• [5] The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist. Jpn J Pharmacol. 1993 Nov;63(3):335-43.
• [6] WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
• [7] Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995 Apr 15;75(12):793-5.
• [8] Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 1994 Jun;23(6 Pt 2):832-7.
• [9] Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999 Aug;34(2):279-84.
• [10] Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994 May;89(5):2212-8.
• [11] WO patent application no. 1995,0216,09, Treatment of normotensive glaucoma with angiotensin ii antagonists.
• [12] DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Clin Pharmacol Ther. 1997 Jan;61(1):59-69.